Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIO… (NCT06568549) | Clinical Trial Compass
RecruitingPhase 4
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
United States350 participantsStarted 2025-06-13
Plain-language summary
The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.
Who can participate
Age range55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Solitary kidney transplant recipient \>55 years of age. At most 1 prior solitary kidney transplant.
* No other solid organ transplant though recipients of autologous stem cell transplants are eligible.
* HIV negative.
* Subjects must be on tacrolimus and mycophenolate mofetil or Myfortic at the time of consent. Prednisone at the time of consent is optional and is per local standard of care. Patients randomized to MMF withdrawal will be placed on prednisone 5mg/d at 4 months. Use of other immunosuppression medications for maintenance (cyclosporine, azathioprine, belatacept, sirolimus) is excluded.
Exclusion Criteria:
Time of Transplant Exclusion Criteria:
* The results of the most recent DSA testing indicate DSA with an MFI \>2000.
* The results of the most recent cPRA testing indicate cPRA is above \>80% (based on MFI \>2000).
4-Month Exclusion Criteria:
* Acute rejection episode either clinical or on biopsy (greater than borderline). Subjects must not experience any type of rejection episodes from the time of transplant and must not show any signs of rejection (Cellular or Antibody mediated rejection, excluding borderline) at their 4-month biopsy (If obtained per standard of care). Subjects experiencing rejection will not be eligible for randomization and MMF withdrawal.
* De novo DSA
* Subjects who are not on tacrolimus at the time of randomization will be placed in the non-randomized group.
* Subjects who at the time of or prior to randomizatio…